Exact Sciences
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
Exact Sciences Nabs FDA Approval for Cologuard Plus Assay
The stool-based test is the next-generation version of Exact's existing Cologuard test for colorectal cancer screening.
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Exact Sciences Enrolls First Patient in Multi-Cancer Early Detection Study
Participants enrolled in the registry study will receive three years of MCED testing and two years of follow-on data collection.
In Brief This Week: CSL Behring Canada, Univercells Technologies, COTA, Texas Oncology
News items for the week of July 15, 2024.